Trimethoprim and enterococci in urinary tract infections: New perspectives on an old issue

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 1, 2008, Pages 35-40

  Wisell, Karin Tegmark ^a   Kahlmeter, Gunnar ^b   Giske, Christian G ^c  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b CENTRAL HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antimicrobial activity; Drug susceptibility testing; MIC; PK PD

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; AMOXICILLIN; AMPICILLIN; BETA LACTAM ANTIBIOTIC; COTRIMAZINE; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; FOLIC ACID; GLYCOPEPTIDE; LINEZOLID; NITROFURANTOIN; PENICILLIN G; PLACEBO; STREPTOMYCIN; SULFAMETHOXAZOLE; SULFONAMIDE; TIGECYCLINE; TRIMETHOPRIM; VANCOMYCIN;

ADVISORY COMMITTEE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTEREMIA; BACTERIUM ISOLATE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG TISSUE LEVEL; DRUG URINE LEVEL; DRUG WITHDRAWAL; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECALIS; ERADICATION THERAPY; EUROPE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; OUTCOMES RESEARCH; PLASMA PROTEIN BINDING; PREDICTION; REVIEW; STEADY STATE; URINARY TRACT INFECTION; WILD TYPE;

ANTI-BACTERIAL AGENTS; ENTEROCOCCUS; FOLIC ACID; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, ANIMAL; TRIMETHOPRIM; URINARY TRACT INFECTIONS;

EID: 45749088956     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn147     Document Type: Review

References (45)

1. Moellering RC Jr. Vancomycin-resistant enterococci. Clin Infect Dis 1998; 26: 1196-9.
2. Taconelli E, Cataldo MA. Vancomycin resistant enterococci (VRE): transmission and control. Int J Antimicrob Agents 2008; 31: 99-106.
3. Amyes SG. Enterococci and streptococci. Int J Antimicrob Agents 2007; 29 Suppl 3: S43-52.
4. Martins Teixeira L, da Glória Siqueira Carvalho M, Facklam RR. Enterococcus. In: Murray PR, ed. Manual of Clinical Microbiology, 9th edn. Washington, DC: American Society for Microbiology, 2007; 430-42.
5. Decousser JW, Bourgeois-Nicolaos N, Doucet-Populaire F. Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria. Expert Rev Anti Infect Ther 2007; 5: 557-71.
6. Giamarellou H. Treatment options for multidrug-resistant bacteria. Expert Rev Anti Infect Ther 2006; 4: 601-18.
7. Nordmann P, Naas T, Fortineau N et al. Superbugs in the coming new decade; multidrug resistance and prospects for treatment of Staphylococcus aureus, Enterococcus spp. and Pseudomonas aeruginosa in 2010. Curr Opin Microbiol 2007; 10: 436-40.
8. Gordon KA, Jones RN. Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America: Comparison report to Europe and Latin America. Results from the SENTRY Antimicrobial Surveillance Program (2000). Diagn Microbiol Infect Dis 2003; 45: 295-301.
9. Hoban DJ, Bouchillon SK, Johnson JL et al. Comparative in vitro potency of amoxycillin-clavulanic acid and four oral agents against recent North American clinical isolates from a global surveillance study. Int J Antimicrob Agents 2003; 21: 425-33.
10. Hamilton-Miller JM. Antibiotic treatment of enterococcal infection. Antimicrob Agents Chemother 1989; 33: 2164.
11. Hamilton-Miller JM. Antibiotic treatment of enterococcal infection. Antimicrob Agents Chemother 1989; 33: 989.
12. Murray BE. Antibiotic treatment of enterococcal infections. Antimicrob Agents Chemother 1989; 33: 1411.
13. Grose WE, Bodey GP, Loo TL. Clinical pharmacology of intravenously administered trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother 1979; 15: 447-51.
14. Kaplan SA, Weinfeld RE, Abruzzo CW et al. Pharmacokinetic profile of trimethoprim-sulfamethoxazole in man. J Infect Dis 1973; 128 Suppl: 547-55.
15. Bruun JN, Ostby N, Bredesen JE et al. Sulfonamide and trimethoprim concentrations in human serum and skin blister fluid. Antimicrob Agents Chemother 1981; 19: 82-5.
16. Cohen J, Powderly WG. Infectious Diseases. St Louis, MO: Elsevier, 2004.
17. Nielsen ML, Laursen H, Stroyer I. Short term treatment of urinary tract infections with trimethoprim/sulfamethoxazole. Scand J Infect Dis 1970; 2: 211-4.
18. Meares EM Jr. Prostatitis: Review of pharmacokinetics and therapy. Rev Infect Dis 1982; 4: 475-83.
19. Jodal U, Fellner H. Plasma and urine concentrations of trimethoprim-sulfadiazine (co-trimazine) in children given one dose per day. Scand J Infect Dis 1988; 20: 91-5.
20. Stachowska B, Senczuk W. Studies on kinetics of sulfadiazine and trimethoprim excretion in man. Int J Clin Pharmacol Ther Toxicol 1987; 25: 81-5.
21. Daily Med Current Medication Information. http://www.dailymed.nlm.nih.gov (12 February 2008, date last accessed).
22. Hamilton-Miller JM. Reversal of activity of trimethoprim against Gram-positive cocci by thymidine, thymine and 'folates'. J Antimicrob Chemother 1988; 22: 35-9.
23. Hill JM, Morse PA Jr, Gentry GA. Metabolism of deoxycytidine, thymine, and deoxythymidine in the hamster. Cancer Res 1975; 35: 1314-9.
24. Zervos MJ, Schaberg DR. Reversal of the in vitro susceptibility of enterococci to trimethoprim-sulfamethoxazole by folinic acid. Antimicrob Agents Chemother 1985; 28: 446-8.
25. Brumfift W, Hamilton-Miller JM. Changing role of co-trimoxazole in the treatment of recurrent urinary infections: A comparison with Augmentin. Br J Clin Pract 1985; 39: 346-51.
26. Brumfift W, Hamilton-Miller JM, Ludlam H et al. Comparative trial of trimethoprim and co-trimoxazole in recurrent urinary infections. Infection 1982; 10: 280-4.
27. Kasanen A, Anttila M, Elfving R et al. Trimethoprim. Pharmacology, antimicrobial activity and clinical use in urinary tract infections. Ann Clin Res 1978; 10 Suppl 22: 1-39.
28. Sitzen W, Rugendorff EW. Co-trimazine once daily in urinary tract infections in comparison with co-trimoxazole given twice daily - a double-blind randomized study. Infection 1981; 9: 91-5.
29. Stratford BC, Dixson S. Results of treatment of 108 patients using trimethoprim plus sulfamethoxazole. Med J Aust 1971; 1: 526-31.
30. Crider SR, Colby SD. Susceptibility of enterococci to trimethoprim and trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother 1985; 27: 71-5.
31. Reid G, Howard L. Effect on uropathogens of prophylaxis for urinary tract infection in spinal cord injured patients: Preliminary study. Spinal Cord 1997; 35: 605-7.
32. Elsner HA, Kruger W, Laufs R et al. Septicemia due to susceptible Enterococcus faecalis despite prophylaxis with trimethoprim-sulfamethoxazole. Eur J Clin Microbiol Infect Dis 1997; 16: 620-2.
33. Goodhart GL. In vivo v in vitro susceptibility of enterococcus to trimethoprim-sulfamethoxazole. A pitfall. JAMA 1984; 252: 2748-9.
34. Chenoweth CE, Robinson KA, Schaberg DR. Efficacy of ampicillin versus trimethoprim-sulfamethoxazole in a mouse model of lethal enterococcal peritonitis. Antimicrob Agents Chemother 1990; 34: 1800-2.
35. Grayson ML, Thauvin-Eliopoulos C, Eliopoulos GM et al. Failure of trimethoprim-sulfamethoxazole therapy in experimental enterococcal endocarditis. Antimicrob Agents Chemother 1990; 34: 1792-4.
36. Farrell DJ, Morrissey I, De Rubeis D et al. A UK multicentre study of the antimicrobial susceptibility of bacterial pathogens causing urinary tract infection. J Infect 2003; 46: 94-100.
37. Jones ME, Karlowsky JA, Draghi DC et al. Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: A guide to appropriate antimicrobial therapy. Int J Antimicrob Agents 2003; 22: 406-19.
38. Frosolono M, Hodel-Christian SL, Murray BE. Lack of homology of enterococci which have high-level resistance to trimethoprim with the dfrA gene of Staphylococcus aureus. Antimicrob Agents Chemother 1991; 35: 1928-30.
39. Huovinen P, Sundstrom L, Swedberg G et al. Trimethoprim and sulfonamide resistance. Antimicrob Agents Chemother 1995; 39 279-89.
40. EUCAST. Antimicrobial Wildtype MIC Distributions of Microorganisms http://www.eucast.org/WT_EUCAST.htm (12 February 2008, date last accessed).
41. Ambrose PG, Bhavnani SM, Owens RC Jr. Clinical pharmacodynamics of quinolones. Infect Dis Clin North Am 2003; 17: 529-43.
42. Ambrose PG, Bhavnani SM, Rubino CM et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore. Clin Infect Dis 2007; 44: 79-86.
43. EUCAST. MIC-breakpoints for Miscellaneous Antimicrobials - Period of Consultation Ongoing. http://www.eucast.org (12 February 2008, date last accessed).
44. Drugdex. http://www.drugdex.com (12 February 2008, date last accessed).
45. Schwartz DE, Ziegler WH. Assay and pharmacokinetics of trimethoprim in man and animals. Postgrad Med J 1969; 45 Suppl: 32-7.